Nipple Sparing Mastectomy Techniques: A Literature Review and an Inframammary Technique

Andrew Y. Ashikari  
*New York Medical College*

Pond R. Kelemen  
*New York Medical College*

Bahar Tastan

C. Andrew Salzberg

Roy H. Ashikari  
*New York Medical College*

Follow this and additional works at: [https://touroscholar.touro.edu/nymc_fac_pubs](https://touroscholar.touro.edu/nymc_fac_pubs)

Part of the [Medicine and Health Sciences Commons](https://touroscholar.touro.edu/nymc_fac_pubs)

**Recommended Citation**
[https://doi.org/10.21037/gs.2017.09.02](https://doi.org/10.21037/gs.2017.09.02)

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu.
Nipple sparing mastectomy techniques: a literature review and an inframammary technique

Andrew Y. Ashikari¹²³, Pond R. Kelemen¹²³, Bahar Tastan¹², C. Andrew Salzberg⁴, Roy H. Ashikari¹²³

¹Ashikari Breast Center, St. John’s Riverside Health System, Yonkers, NY, USA; ²NYP/Hudson Valley Hospital, Cortlandt Manor, NY, USA; ³Department of Surgery, New York Medical College, Valhalla, NY, USA; ⁴Department of Plastic Surgery, Icahn School of Medicine, Mount Sinai Health System, New York, NY, USA

Contributions: (I) Conception and design: AY Ashikari; (II) Administrative support: None; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: AY Ashikari, B Tastan; (V) Data analysis and interpretation: AY Ashikari, PR Kelemen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Andrew Y. Ashikari, MD. Director, Ashikari Breast Center, St. John’s Riverside Health System, Yonkers, NY, USA; Chairman, Department of Surgery, NYP/Hudson Valley Hospital Center, Cortlandt Manor, NY, USA; 128 Ashford Avenue, Dobbs Ferry, NY 10522, USA. Email: andrewash@optonline.net.

Abstract: Nipple sparing mastectomy (NSM) has quickly become an accepted technique for patients with selected cancers and for risk reducing surgery. Much of its surgical acceptance over the last decade has been based on the low risk of nipple areolar complex (NAC) occurrence in breast cancer patients. Improved patient satisfaction due to improved cosmetic outcomes with reconstruction have also driven its popularity. We reviewed current English journals to determine the NSM techniques which achieve the lowest complications, best outcomes, and best patient satisfaction. We researched studies showing reductions in complications with improved surgical techniques and patient selection which have been implicated in improved results. In the studies reviewed, incision placement, away from the nipple, resulted in the lowest rates of ischemic nipple complications and the best cosmetic outcomes. The effect of other factors such as surgeon experience and thickness of skin flap development were more difficult to prove. Leaving a 2–3 mm rim of tissue around the nipple bundle was shown to help preserve the nipple vascularity. Lower complication rates with improved outcomes and patient satisfaction were reported in the literature in patients with B or smaller cup sizes, non-smokers, and patients with lower body mass index (BMI). Incision placement, away from the nipple, with preservation of a 2–3 mm rim of tissue around the nipple bundle along with careful patient selection were the most significant variables reviewed which helped to lower complications rates of NSM. Coordinated surgical planning with the breast and plastic surgeons to determine the best surgical approach for each individual patient is necessary to obtain the best results. Although short-term oncologic follow-up seems to be acceptable, longer follow-up will still be needed to define the best breast cancer surgical candidates for the nipple sparing approach.

Keywords: Nipple sparing mastectomy technique; nipple sparing mastectomy complications; nipple sparing mastectomy cosmesis; nipple sparing mastectomy satisfaction; nipple sparing mastectomy incisions; nipple sparing mastectomy vascular supply

Submitted Jul 05, 2017. Accepted for publication Aug 28, 2017.
doi: 10.21037/gs.2017.09.02
View this article at: http://dx.doi.org/10.21037/gs.2017.09.02
Introduction

Less aggressive surgical management of breast cancer patients has made major advances over the last 3 decades with the rebuke of the Halstedian concept to acceptance of a more systemic approach to the management of breast cancer patients. Surgery has become more conservative starting with Bernie Fisher's proven concept of breast conservation in the 1980's and then the advent of sentinel lymph node (SLN) evaluations and skin sparing mastectomies in the 1990's. With studies proving the low risk of nipple areolar complex (NAC) involvement in select cancer patients (1-3) and the new genetic era of breast cancer risk, it was only natural that nipple sparing techniques would be developed in the late 1990's and at the turn of the century. In 1999, Lynn Hartmann's paper (4) in the NEJM showed the benefit for prophylactic, or better termed risk reducing nipple sparing mastectomy (NSM), in high risk patients with a 90% reduction in breast cancer development. This first started the movement towards the nipple sparing approach. Meijers-Heijboer's later study (5) in the NEJM along with other publications (6-9) then proved the advantages of risk reducing mastectomy in BRCA+ patients. These cancer reduction benefits along with the improved aesthetic outcome from optimal breast contouring with minimal scarring and improved patient satisfaction led to the NSM's quick acceptance and implementation into breast surgery practices.

The use of the NSM in cancer patients is more controversial and though it has become standard practice in many early stage cancer patients, who require or request a mastectomy, there are no controlled clinical trials evaluating its effectiveness. The initial use of the nipple sparing approach was spurred by evidence showing a low risk of NAC involvement in the pathological mastectomy specimens of smaller cancers (less than 2 cm) which are node negative, more peripherally located (>2 cm from the nipple), and localized (1-3) (Table 1). This led various institutions to begin performing NSMs in this well-defined lower risk group of breast cancer patients with good short-term cancer outcomes (10-13). This has now progressed to the expansion of eligibility criteria with some institutions advocating for its use in higher risk patients with larger tumors, tumors close to the nipple, or even in patients with more aggressive cancers after neoadjuvant chemotherapy (14). Its utilization has also increased with the greater use of mastectomy and contralateral prophylactic mastectomy (15,16) especially in the younger aged breast cancer population (17,18). To date, only one meta-analysis (19) has critically analyzed overall survival (OS), disease-free survival (DFS), and local recurrence (LR) in cancer patients who underwent NSM showing no significant differences compared to women undergoing modified radical mastectomy (MRM) or skin sparing mastectomy (SSM). This meta-analysis is limited in that it focuses mainly on short-term follow-up studies in earlier stage cancer patients. The American Society of Breast Surgeons (ASBS) currently has an on-going registry trial tracking NSM patients throughout the United States to help better define patient outcomes and eligibility criteria in the future.

In this review, we have attempted to search for the best studies of the NSM approach to determine the optimum technique with the lowest complication rates, trying to identify the technical causes of the most common complications and the best methods to avoid them. We focused on studies evaluating surgeon specific variables as well as patient variables which help to reduce post-operative complications. We only briefly mention the clinical oncologic indications for the procedure and cancer specific outcome data as well as specific reconstruction technique unless it had some bearing on overall complication or outcome since these topics are being described elsewhere in this journal edition.

Methods

We researched articles using MEDLINE and PubMed using the MeSH headings for “nipple sparing or total SSM, technique, complications, outcomes, or satisfaction”. We performed a world-wide search of all English language journals. We chose relevant articles which focused mainly on technical factors including complications and patient satisfaction.

Results

SLN biopsy in prophylactic surgery

The use of SLN biopsy in prophylactic surgery has been studied in at least three separate institutional studies showing the frequency of occult cancer in prophylactic mastectomy patients to be less than 10% with the majority of the occult cancers found to be ductal carcinoma in situ (DCIS) (20-22) (Table 2). The rate of occult invasive cancers, being less than 5%, does not justify the use of routine SLN biopsy for patients undergoing nipple sparing mastectomies.
Table 1 Occult nipple areolar cancer involvement

<table>
<thead>
<tr>
<th>Studies</th>
<th>Years</th>
<th>Number of mastectomy specimens</th>
<th>Nipple areolar complex involvement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laronga et al. (1)</td>
<td>1999</td>
<td>246</td>
<td>5.6</td>
</tr>
<tr>
<td>Simmons et al. (3)</td>
<td>2002</td>
<td>217</td>
<td>10.6</td>
</tr>
<tr>
<td>Lagios et al. (2)</td>
<td>1979</td>
<td>149</td>
<td>30.2*</td>
</tr>
</tbody>
</table>

*, 95% of tumors <2.5 cm from the nipple.

Table 2 Incidence of breast cancer in prophylactic mastectomy specimens

<table>
<thead>
<tr>
<th>Authors</th>
<th>Institutions</th>
<th>Study years</th>
<th>Number of patients</th>
<th>Number of invasive cancers (%)</th>
<th>Number of noninvasive cancers (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soran et al. (22)</td>
<td>UPMC</td>
<td>1999–2004</td>
<td>155</td>
<td>2 patients (1.3)</td>
<td>3 patients (1.9)</td>
</tr>
<tr>
<td>Black et al. (21)</td>
<td>Mass General</td>
<td>1999–2005</td>
<td>173</td>
<td>5 patients (2.9)</td>
<td>14 patients (8.1)</td>
</tr>
<tr>
<td>Boughey et al. (20)</td>
<td>MD Andersen</td>
<td>2000–2005</td>
<td>409</td>
<td>8 patients (2.0)</td>
<td>14 patients (3.4)</td>
</tr>
</tbody>
</table>

in the prophylactic setting.

Incision placement

Various incision locations have been described for NSMs with individual surgeons or institutions tending to favor certain approaches (23–27). The incisions used most frequently were best evaluated by Endara et al. (26) who analyzed 48 pooled NSM studies from the literature with 41 studies describing the mastectomy incision and 11 studies evaluable for outcomes by incision type which found the most common incision used was a radial approach (46%) followed by the periareolar (27%), and the Inframammary incision (21%). The Endara et al. (26) study also looked at nipple necrosis rates associated with incision placement in the same 11 studies which included 543 procedures and found the lowest rates of nipple necrosis in the incisions involving the least circumference of the nipple (radial incision, 8.83%; inframammary, 9.09%; periareolar/circumareolar, 17.81% and transareolar, 81.82%). Increased risk of nipple areolar necrosis associated with periareolar incisions was also seen in an Italian study by Salgarello et al. (28) where it was seen as an early complication in 4 of the breasts [9.5% (4/42) of total NSMs] with periareolar incisions but in none of the 22 breasts with radial incisions undergoing NSM from 2004 to 2009.

An earlier single institution study which evaluated incision location and nipple necrosis rates was performed at University of California, San Francisco (UC-SF) and published by Wijayanayagam et al. (29) and Garwood et al. (13) and reported two general types of incisions crossing either >30% of the NAC (NAC crossing, mastopexy, nipple free grafts) or <30% of the NAC (inframammary, radial, or lateral/infrolateral) (Figure 1). Patients were divided into 2 cohorts, an earlier group of 64 NSM procedures from 2001 to 2005 where more NAC crossing incisions were performed vs. a later cohort of 106 NSM procedures from 2005 to 2007 where fewer NAC crossing incisions were performed. There was a significant increase in nipple survival rates (80–95%, P=0.003) and decrease in necrotic complications (30–13%, P=0.01) in the later cohort. A further follow-up study by Warren Peled et al. (11) from UC-SF compared their first 100 NSM cases with the following 557 NSM cases with the following 557 NSM cases and continued to show decreased complications involving both nipple and mastectomy flap necrosis as well as reductions in expander/implant loss which they again attributed to fewer NAC crossing incisions (mainly inframammary or limited superior areolar incisions) as well to reduced use of direct to implant reconstruction and the selective use of acellular dermal matrixes (ADMs) during reconstruction.

Overall cosmetic and satisfaction outcomes as related to incision types have been reported but not statistically analyzed by a few individual studies (23,25,30–33). A retrospective study by Djohan et al. (32) best evaluated cosmesis and patient satisfaction using postop questionnaires of 78 patients as well as independent observer opinions. Seventy-three percent of the patients stated that they would undergo the surgery again. Decreased nipple sensation/arousal was the most common complaint followed by lateral
displacement of the nipple. Nipple displacement was felt to be related to the radial incision used for the majority of the NSMs and was related to scar contraction. A separate study by Wagner et al. (30) evaluated cosmetic outcomes of 26 patients who underwent NSM through independent evaluations by two plastic surgeons 6 months after surgery. There was an acceptable (excellent, very good, or good) appearance in the breasts of 73.1% of the patients and in the NAC of 55.8% of the patients. The biggest cosmetic problem was described as lateral displacement of the nipple in 67.4% of patients or lateral displacement of the breast in 50% of the patients and this was felt to be due to the lateral incision placements in the majority (79.6%) of the patients. Other single institution studies have suggested that keeping the incisions in the inframammary (25) or inferolateral (23,34) positions (away from the nipples) does not result in nipple lateralization and also offers better concealment of the incision. Moyer et al. (33) reported on a retrospective database evaluation of NSMs in 26 patients (40 NSMs) performed from 2009 to 2010 where postoperative photographs were evaluated by four reviewers. Circumareolar incisions were associated with a
nipple necrosis rate of 75% compared with 33% for radial incisions and 27% for inframammary incisions and were related to worse aesthetic evaluations. Not one of these studies was set up to statistically evaluate the cosmesis and satisfaction rates of NSM independent of the incision type and they are just single institution observations.

Preserving the vasculature

The maintenance of the NAC viability and skin flap perfusion has been studied in past female breast cadaveric studies by van Deventer et al. (35) and O’dey et al. (36). The NAC gets the majority of its blood supply from the internal thoracic vessel with its medial perforators and the lateral thoracic vessel (Table 3). O’dey et al. (36) suggested that medial and lateral based pedicle flaps (superomedial and superolateral) may provide the best blood supply to the nipple which would favor a more inferior incision to preserve these pedicles. If a radial incision is used then a more lateral incision would be favored to help preserve as much of the internal thoracic blood supply coming off the medial flap as possible. A full-thickness glandular dermal skin flap dissection, leaving much of the subdermal fat, was also felt to be beneficial for vascular preservation as opposed to a thinner split-thickness lipo-dermal flap, where more of the subdermal fat is removed.

Preservation of the NAC

We found no studies that were designed to determine exactly how to handle the thickness of tissue left under the NAC with different surgeons applying different techniques and strategies. Studies have not been specifically controlled to determine if either everting and coring the nipple to remove all the visible ductal tissue (27,29) vs. a more conservative approach of leaving a visible rim of tissue in and around the nipple and areola (24,37) leads to better nipple viability. Petit et al. (38) from Milan reported on follow-up at 5 years of 1,001 NSMs where ELIOT and intraoperative radiation, was applied to the retroareolar residual nipple tissue with excellent results (nipple necrosis rate of 3.5%). Another study from Rusby et al. (39) looked at the microscopic anatomy of the NAC in 7 non-irradiated and 5 irradiated nipples and found that removal of the duct bundle in the center of the nipple and leaving a 2 or 3 mm peripheral rim of subcutaneous tissue around the nipple removed 96% (2 mm) and 87% (3 mm) of the ductal tissue, respectively. The study also found that leaving a 2 or 3 mm peripheral rim of subcutaneous tissue around the nipple retains 50% (2 mm) and 66% (3 mm) of the vascularity of the nipple, respectively and that radiation did not affect the vascular density of the ductal tissue in the nipple. These individual institutional trials and studies give some experimental support to validate the concept of acceptable NAC viability yet good ductal tissue clearance with the technique of leaving small residual rims of retroareolar breast tissue during NSMs.

The use of a “delay phenomenon” by creating a surgical wound to improve the blood supply to the NAC prior to the NSM has also been described with good results (40,41). The procedure involves a periareolar incision to elevate a plane beneath the NAC 1–3 weeks before the planned NSM and thus stimulating improved blood supply to the wounded tissue. Jensen et al. (41) emphasized its use, without any NAC loss, in 20 patients with prior areolar incisions, significant ptosis, or smokers. In lower risk patients, where 360° dermal perfusion could be preserved, however, its use was not felt necessary.

Pathologic assessment of the NAC

Intraoperative pathologic evaluation of the NAC to

<table>
<thead>
<tr>
<th>Arterial supply</th>
<th>O’Dey et al. (36) (%)</th>
<th>van Deventer (35) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal thoracic artery: medial pedicle</td>
<td>86</td>
<td>100</td>
</tr>
<tr>
<td>Lateral thoracic artery: lateral pedicle</td>
<td>100</td>
<td>70</td>
</tr>
<tr>
<td>Anterior intercostal branches: medial and inferior pedicle</td>
<td>71</td>
<td>74</td>
</tr>
<tr>
<td>Thoracoacromial high thoracic artery: superior pedicle</td>
<td>57</td>
<td>7.4</td>
</tr>
<tr>
<td>Posterior intercostal branches: lateral and inferior pedicle</td>
<td>N/A</td>
<td>4</td>
</tr>
</tbody>
</table>

NAC, nipple areolar complex; N/A, not available.
determine preservation was initially a standard during all NSMs to determine, intraoperatively, if the NAC could be preserved in patients. This has recently been abandoned by some practices (24) due to rare instances of positive biopsies. Its use was also questioned in a poster from the ASBS registry (42) due to the low rates of intraoperative involvement (2/104 NAC biopsies) and 2 nipples removed due to false positive intraoperative results which were read as indeterminate or suspicious and were found to be cancer-free after the nipples were removed intraoperatively.

**Tumescence**

The use of tumescence as an aid in raising skin flaps to decrease bleeding using lactated ringer's solution containing 1% lidocaine and dilute (1:1,000) epinephrine has been previously described for use in mastectomies (43). Tumescence was not shown to be an independent variable affecting post-operative complications including infection, flap necrosis, hematoma, seroma, or epidermolysis in two separate studies of non-NSMs performed by Khavanin et al. (44) and Abbott et al. (45). It has not been well studied in NSM patients and is currently being used as an aid in some institutions to decrease bleeding with sharp (scissor or knife) dissection to avoid electrocautery thermal injury to the skin but should be used with caution because of the temporary vasoconstrictive properties of the epinephrine. I could only find one paper which statistically evaluated tumescence in NSM but solely related to expander reconstruction in 966 patients undergoing SSM and NSM (46) which found that tumescence was an independent risk factor associated with increased flap necrosis (12.8% with tumescence vs. 6.7% without) in those patients who had high intraoperative expander fill volumes (>66% maximal fill volume).

**Surgeon experience**

There is suggestive evidence and good reason to believe that surgical experience plays a role in reducing complications and improving outcomes in NSM but only one study performed by Gould et al. (47) specifically analyzed surgical experience with complications, specifically nipple necrosis rates. In this study, there was no significant reduction in nipple loss rates with surgeon experience of 1–2 cases (15%) vs. 3–10 cases (23%) vs. >10 cases (20%). This study, however, goes against other institutional experiences with larger numbers of cases showing improved complication rates as surgical experience and technique improves (13,24,27,32,34). Garwood et al. (13) in the 2-cohort study showed a significant decrease in necrotic skin complications (30% to 13%) and an improvement in nipple survival (80% to 95%) with a later cohort of NSM patients performed from 2005 to 2007 compared to an earlier cohort from 2001 to 2005. A retrospective study by Colwell et al. (34) of 500 consecutive NSMs from 2007 to 2012 showed a 5-year trend towards inferolateral/inframammary incisions with lower complication rates shown by multivariate analysis [odds ratio (OR), 0.018; 95% CI, 0.00260–0.12089] which helped to modify their subsequent incisions. Crowe et al. showed improvements in NAC viability comparing a 2004 study (48) of 54 NSMs vs. a 2008 paper (27) of 149 NSMs with the later paper using only laterally and the earlier paper using medially placed incisions without NAC loss in their later experience.

**Selection factors**

Surgical selection criteria have to be considered when performing NSMs. Reviewed studies showed no difference in complication rates (30,47) or patient satisfaction rates (10) when the NSM was performed for cancer (therapeutic) or for prophylactic reasons. Bilateral NSM procedures compared to unilateral procedures, in the study by Wagner et al. (30), showed no increase in complication rates as well. A single institution retrospective review from 2003 to 2011 by Gould et al. (47) comparing 113 NSM cases to a matched group of 120 SSM controls (28% vs. 27%) also found no significant differences in overall complication rates.

Patient specific selection criteria, however, does affect the outcome of NSMs. The effect of these patient specific variables on complication rates have not been well studied but has been best described by Gould et al. (47) in a series of 73 women who underwent NSMs from 2003 to 2011. BMI, diabetes mellitus, hypertension (HTN), and smoking showed a nonsignificant trend towards worsening complications of nipple necrosis. Large bra cup size (C or larger) was the only statistically significant patient factor with a higher nipple necrosis rate of 34% compared to only 6% with B or smaller cup sizes. Djohan et al. (32), in his patient satisfaction survey of 78 NSM patients, also correlated lower patient satisfactions and increased complications with larger breasts and increased BMI. BMI, smoking and preoperative radiation were associated with higher total complication rates in the study by Colwell et al. (34) which evaluated 500 NSMs from 2007 to 2012. In the 2-cohort study by Garwood et al. (13) smoking was also
a statistically relevant independent variable associated with increased skin/nipple necrosis rates.

Reconstruction methods

Reconstruction method has also been linked to complications associated with NSM. Endara et al. (26) reported a pooled analysis study which compared 5 2-stage implant reconstruction studies vs. 5 direct to implant reconstruction studies vs. 2 autologous reconstruction studies and resulted in complication rates of 52.8%, 16.7%, and 23.7% with nipple necrosis rates of 4.5%, 4.1%, and 17.3%, respectively. Gould et al. (47) showed no significant effect of reconstruction type on nipple necrosis complications in the 113 NSM cases evaluated but there was a trend toward higher nipple necrosis rates with autologous vs. either 2-stage or direct to implant reconstructions (40% vs. 18.5%, P=0.23). In comparing the 2-stage vs. the direct to implant reconstruction, Colwell et al. (34) did not see a difference in complication rates in the 500 NSMs evaluated however, with experience they have developed selection criteria using the 2-stage reconstruction more selectively in patients at higher risk of nipple or skin flap necrosis (e.g., smokers, higher BMI). In Garwood et al.’s (13) 2-cohort study, a higher rate of necrotic skin complications resulted with immediate implant reconstruction in their initial cohort of NSM patients causing them to switch to 2-stage reconstructions in their later cohort of NSM patients with a reduction in the complication rate. In that study, autologous reconstruction still accounted for the highest skin necrosis complication rates of all of the reconstruction techniques (37% autologous complication rate vs. 18% for direct to implant vs. 7% for 2-stage reconstruction).

The inframammary nipple sparing technique (Figure 2)

Our initial experience and technique of NSM from 1988 to 2007 including 67 patients has been previously described (49) with the majority of our procedures performed prophylactically (79%). We have now performed over 600 NSMs with 95% performed by one breast surgeon (AYA) and one plastic surgeon (CAS). Since our initial paper, we have seen a significant increase in the numbers of NSMs performed for cancer as acceptance and eligibility has expanded.

Our technique involves a coordinated approach with our reconstructive surgeons especially as it relates to patient factors including comorbidities and breast size which have been shown to have significant impacts on outcomes. If large breast size or significant ptosis is felt to affect outcome, we have adopted Dr. Spear’s described technique (50) of a staged reduction mastopexy and delayed NSM, if the clinical situation allows. Previous augmentation, previous breast surgery, and even prior radiation have not been absolute contraindications for the procedure in our practice.

We perform MRI preoperatively in all our patients who are felt to be NSM candidates to rule out possible mammographic and ultrasound occult tumors in high-risk patients choosing risk reducing NSM and to determine eligibility of NSM in early breast cancer patients. We will allow multifocality as long as the tumors are >2 cm from the nipple and the disease is contained to one quadrant.

We begin by marking out symmetrical inframammary incisions with our plastic surgeon. The incision length varies from 8–11 cm depending on the breast anatomy in order to obtain appropriate exposure. Larger incisions can be required in some of the larger breasts or in patients with dense breast tissue where the skin is fairly taught. We have performed longer, more medially base inframammary incisions to allow for internal mammary artery access for deep inferior epigastric perforator (DIEP) flap reconstructions in selected cases. The incisions are planned to lie in the new inframammary fold as determined preoperatively by the reconstructive surgeons (usually about 7.5–8.0 cm from the nipple). Once the incision is made, the superior skin flap is everted with the non-dominant hand and the breast tissue retracted inferiorly with two Adair clamps. The plane between the subcutaneous fat and the glandular tissue is developed to preserve the dermal blood supply. We have used sharp knife dissection but typically use the Peak PlasmaBlade™ radiofrequency device (Medtronic, Palo Alto, CA, USA). We do not use tumescence in order to prevent any short-term effect of vasoconstriction related to the epinephrine. Care must be taken while raising the initial inframammary flap below the nipple because this is the most ischemic part of the skin flap and surgeons often strip too much of the subcutaneous fat in this area exposing the dermal vessels to injury. The breast tissue is freed using this skin eversion technique past the posterior aspect of the NAC with only a small approximately 2–3 mm thick rim of breast tissue visibly left under the NAC. The nipple itself is not inverted and cored, in our technique, to prevent increased risks of nipple ischemia. Once the skin flap is developed to a plane where direct visualization is impossible by the skin eversion technique, lighted fiberoptic retraction (Invuity™, Invuity, San Francisco, CA or LightMat™,
Cura Surgical, Geneva, IL, USA) is used to visualize the plane superiorly up to the infraclavicular region, medially to the sternum, and laterally to the latissimus. Care is taken to preserve the intercostal perforators coming medially off the sternum which can supply a significant vascular supply to the skin flaps. Finally, electrocautery is used to remove the breast off the pectoralis major muscle. The axillary tail of the breast is the highest and most difficult to visualize, so this region is typically dissected last so as to use the countertraction of the breast to better visualize and remove these last breast/skin attachments. A retroareolar biopsy is then taken as a shave biopsy underneath the nipple and sent for intraoperative frozen section analysis and if positive for cancer, the NAC is removed through a separate horizontal elliptical incision during the same procedure. The breast tissue is often weighed by the plastic surgeons to help them determine the subsequent reconstruction volumes. The skin flaps are then visualized and trimmed, if necessary, to remove any residual breast tissue and to ensure even flaps.

SLN biopsies are performed only in therapeutic cancer cases through a small separate axillary incision which can also be used to help visualize and assist in the removal of the axillary breast tissue. Tc$^{99}$ is used alone without using either methylene blue or isosulfan blue dye to prevent the vasoconstriction associated with the blue dyes and potential effects on nipple viability. We use intraoperative

![Figure 2](image_url)
skin angiography (SPY Elite™, Novadaq, Ontario, Canada) in most of our cases at two separate time points, after the mastectomy and after the reconstruction to evaluate the skin flaps. There is limited data to quantify the absolute risk of skin flap necrosis with this device but we have found it helpful to identify possible areas of concern which we will monitor more closely. Since we use intraoperative skin angiography, we do not use tumescence since it causes significant vasoconstriction and poor visualization of the dermal vessels during angiography, making any predictions of skin/nipple viability nearly impossible. An upper body warmer (Bair Hugger™, 3M, St. Paul, MN, USA) is kept on our patients for the first 24 hours to help prevent vasoconstriction. For post-operative pain control, we have used a variety of methods including Marcaine pumps (On-Q, Halyard Health, Irvine, CA, USA) placed subcutaneously under the skin flaps as well as pre-operative pectoral nerve blocks and more recently liposomal bupivacaine (Exparel™, Pacira Pharmaceuticals, Parsippany, NJ, USA) injected into the pectoral muscle just prior to reconstruction.

**Discussion**

The concept and technique of NSM was originally described by Freeman in the 1960's (51) but it was only described for high-risk patients since it was not accepted for cancer patients as the dogma of radical extirpation of cancer persisted up until the 80's. As the BRCA gene was identified by Mary Claire King in the 1990's, the NSM made a resurgence as an accepted procedure for high-risk patients with its reintroduction by Hartmann et al. (4) and later benefits reported in the BRCA population (5,6,8,52).

The beginning of the century then saw the use of NSMs in cancer patients with some encouraging initial follow-up results (10,19,26,38,53,54) as measured by short term OS and LR rates. Of the papers with reasonable follow-up data, Endara et al. (26) reported locoregional recurrence rates (LRR) of 1.8% and distant metastasis rates (DM) of 2.2% in 28 pooled studies but follow-up was short ranging from 0.2–210 months and the tumor types and characteristics were not independently reported in the study. A meta-analysis reported by De La Cruz et al. (19) looked at eight studies comparing NSM with MRM/SSM with no statistically significant differences between the treatment groups in terms of use of adjuvant or neoadjuvant chemotherapy, use of adjuvant radiation, estrogen receptor (ER) or progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2)/neu status, lymph node status or tumor sizes. Five of the 8 studies compared DFS with a 9.6% risk benefit for NSM, 5 studies compared OS with a 3.4% risk benefit for NSM, and 8 studies evaluated LR with a 0.4% benefit for NSM. None of these benefits for DFS, OS, or LR were statistically significant, however. Follow-up times ranged from 25 to 101 months. Gerber et al. (54) compared LRR, DM, and breast cancer specific death rates in a series of 238 patients from 1994–2000 who were candidates for MRM with tumors greater than 2 cm from the nipple and no skin involvement, and were then offered either SSM, NSM, or MRM. Forty-eight patients underwent SSM, 60 patients underwent NSM, and 130 patients underwent MRM and no significant differences resulted after a mean follow-up of 101 months (LRR: 10.4% SSM, 11.7% NSM, 11.5% MRM, P=0.974; DM: 25% SSM, 23.3% NSM, 26.2% MRM, P=0.916; breast cancer specific death: 20.8% SSM, 21.7% NSM, 21.5% MRM, P=0.993). The largest prospective trial reporting outcomes of NSM for cancer at 13-year median follow-up was from the Karolinska Institutet in Sweden and reported by Benediktsson et al. (53). They followed 216 patients from 1988 to 1994 who underwent unilateral NSM for a variety of cancers (13.3% DCIS, 33.3% stage I, 37.9% stage II, 15.3% stage III) and showed a DFS of 51.3%, OS of 76.4%, LRR of 24.1%, and DM rate of 20.3%. The OS rates were considered acceptable compared to other Swedish trials of MRM at that time. The LRR was considered high and the follow-up of the patients who had a LRR (most had repeated local excisions and some with radiation therapy as well) showed no effect on their OS which is not the usual outcome for patients with recurrences after mastectomy. The Benediktsson study included a high percentage of patients with multifocality (73.6%), tumors >2 cm (35%), patients with positive lymph nodes (40.3%) and also used an older, less aggressive surgical technique for full breast tissue removal which may have also accounted for the higher LRR.

Cancer specific indications are not being specifically addressed in this paper but were available in many of the articles reviewed. There is no unanimity in the selection of cancer patients across many of the articles written on NSM. It can be argued however, that given the current available studies and lack of long-term cancer outcome, careful patient selection of patients undergoing NSM should be considered. These patients typically include isolated tumors <2.5 cm, >2 cm from the nipple, and without skin involvement.

During the initial introduction of NSM to both high-risk and cancer patients, it was felt that complication
rates especially for skin/nipple necrosis would be too high to justify its use. It took time to implement its use in many programs but as the initial results began showing acceptable complication rates (Table 4), the technique took hold so that its use became universally accepted though individual selection criteria vary. Nipple and skin flap necrosis rates have typically fallen to rates between 5–10% with most being treated conservatively without full nipple loss. Complication rates have also fallen with improved experience and technical improvements as was seen in the papers by Garwood et al. (13) and Colwell et al. (34) where keeping the incisions away from the nipple (encompassing <30% of the NAC) and using inframammary incisions improved their complications. Better understanding of the NAC and skin flap blood supply as shown by O’dey et al. (36) and van Deventer (35) have also improved our ability to place incisions away from the major blood supply, the medial internal mammary artery, and have helped us understand the ability of the nipple to survive with minimal 2–3 mm rims of residual periareolar tissue while still removing the majority of the ductal tissue.

Developing the skin flaps and preserving blood supply has also been enhanced by our understanding of the vascular anatomy but it should also be noted that there is significant patient variability in skin flap thickness required to adequately remove the majority of the breast tissue while preserving the dermal blood supply. Figure 3 depicts a picture of two separate mammograms of two totally different patients where the skin flap thickness needs to be varied. A smaller lean patient will typically have a thin subdermal fat plane and thus require a thinner flap to remove all the breast tissue while maintaining the dissection in the glandular-dermal plane to keep the dermal vasculature intact. A larger patient can have a thicker subdermal fat plane, especially away from the NAC and care must be taken to not make the flap so thin that most of the subdermal fat is dissected away (lipo-dermal plane) which will remove more dermal vasculature and thus increase flap necrosis rates and complications.

The use of sharp (knife) vs. electrocautery dissection in raising the anterior skin flap is operator dependent. Sharp dissection often leads to increase blood loss and tumescence is often considered. Though there are no specific papers evaluating the risk of complications with NSM alone, tumescence has been used in NSM with acceptable outcomes (44). I personally like to use the peak PlasmaBlade™ (Medtronic, Palo Alto, CA, USA) and do not use tumescence while raising my skin flaps since the PlasmaBlade™ causes less thermal injury than the standard electrocautery due to a more precise area of action, especially when using the cutting function. I do not like the temporary vasoconstriction which occurs with the use of epinephrine with the use of tumescence. In my practice, we also use the SPY Elite™ (Novadaq, Ontario, Canada) intraoperative skin perfusion testing of the flaps after our mastectomies and after our reconstructions to evaluate our skin flap perfusion. This has helped us to better evaluate our surgical techniques in real time and gives us immediate feedback as to the vascular integrity of our flaps. Though there are few publications on its ability to predict flap necrosis in NSM (55), we find it a good qualitative perfusion test that has been able to help predict skin loss in virtually all our cases where it has occurred. The use of tumescence and associated vasoconstriction significantly affects the intraoperative perfusion testing, making the test difficult to interpret.

In the studies reviewed, patient selection factors had a significant effect on both cosmetic outcomes and complication rates. Most of the studies of NSM were highly selective in their patient populations and current smokers

**Table 4** Studies showing NSM complication rates

<table>
<thead>
<tr>
<th>Study institution, year</th>
<th>Number of procedures [patients]</th>
<th>Complications [n (%)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>UC-SF, 2012 (11)</td>
<td>657 [428]</td>
<td>Hematoma: N/A, Infection: 117 (17.8), Flap necrosis: 78 (11.9), Nipple necrosis: 23 (3.5), Implant loss: 56 (9.9)</td>
</tr>
<tr>
<td>MSKCC, 2011 (12)</td>
<td>353 [200]</td>
<td>Hematoma: 0 (0), Infection: 6 (2.0), Flap necrosis: 69 (19.5), Nipple necrosis: 13 (3.5), Implant loss: 3 (1.0)</td>
</tr>
<tr>
<td>MD Anderson, 2012 (30)</td>
<td>54 [33]</td>
<td>Hematoma: N/A, Infection: 0 (0), Flap necrosis: 6 (10.0), Nipple necrosis: 3 (5.6), Implant loss: N/A</td>
</tr>
<tr>
<td>Mass General, 2014 (34)</td>
<td>482 [267]</td>
<td>Hematoma: 8 (1.7), Infection: 16 (3.3), Flap necrosis: 25 (5.2), Nipple necrosis: 21 (4.4), Implant loss: 9 (1.9)</td>
</tr>
<tr>
<td>Milan, 2009 (38)</td>
<td>1,001 [1,001]</td>
<td>Hematoma: N/A, Infection: 20 (2.0), Flap necrosis: N/A, Nipple necrosis: 35 (3.5), Implant loss: 43 (4.3)</td>
</tr>
</tbody>
</table>

NSM, nipple sparing mastectomy; N/A, not available.
as well as high BMI, large or ptotic breast, or patients with prior breast irradiation were excluded from NSMs (12,24,30,56). All of these factors seem to contribute to increased complications in the various studies reviewed which analyzed these patient factors (13,32,34,47) and should be carefully considered when selecting patients as candidates for NSM.

Overall cosmesis and patient satisfaction have been shown to be good to excellent in the NSM studies reviewed (10,28,31-33,54) and there are definite improvements seen in aesthetic outcomes in the studies comparing SSM with NSM (18,33). Complication rates have been shown to negatively affect satisfaction scores to a greater degree in prophylactic mastectomy patients as compared to the patients undergoing mastectomies for cancer (57). Dissatisfaction with nipple sensation and arousal scores associated with NSMs are common (32) though there have been no technical methods shown to improve these results. The only technical factors considered in the reviewed studies that helped improve nipple necrosis complications and patient cosmesis and satisfaction were incision placement away from the nipple which deceased nipple necrosis rates (33) and non-radial incisions which decreased nipple lateralization (28,32).

There have been several methods used to try to perform NSMs on larger or ptotic breasted women. We have preferred a staged reduction mastopexy procedure as described by Spear et al. (50), especially for prophylactic patients whose surgeries can be delayed. Full-thickness nipple grafting has also been used and is well described but is associated with increased nipple losses. Dietz et al. (58) has also described a unique technique of nipple preservation with a reduction procedure performed during the surgery and preserving the dermal vessels to the NAC by deepithelializing the surrounding skin of the nipple to perform the reduction yet preserve the NAC vasculature without a full-thickness graft.

The use of an endoscopic technique in performing NSMs for cancer patients has also been described by Sakamoto et al. (59,60) from Japan who uses a combination of an axillary and periareolar incision to perform the dissection off of the pectoralis fascia and the anterior skin flaps, respectively. The axillary incision is first used for the SLN biopsy. They had good results in their initial paper (59) including 87 patients from 2002 to 2005 but noted significantly higher rates of nipple necrosis with nipple coring (41%) vs. non-coring (18%) of the nipple. The follow-up paper from 2016 (60) included 404 patients and 421 breasts with a very acceptable LRR of 2.6% after a median follow-up of 61 months. Age <40 years, stage III cancer, and inadequate surgical margins were significant variables associated with LRR.

Figure 3 Mammogram depiction of raising the glandular-dermal plane. (A) Patient with thin subdermal fat plane; (B) patient with thicker subdermal fat plane.
In regards to reconstructive techniques, current studies would suggest that autologous reconstruction is associated with increased complication rates when performed with NSMs (13,26,47). Despite these initial concerns, autologous reconstruction has its benefits and should not be abandoned as an option in well selected patients. In our particular practice, direct to implant reconstruction has given excellent immediate cosmetic results in the majority of patients undergoing NSM with acceptable complication rates and can still be an option in larger or ptotic patients in combination with prior reduction mastopexy (50). It also has the added benefit of avoiding an unnecessary second procedure for the patient. We routinely use acellular dermal matrix (AlloDerm, Allergan, Dublin, Ireland) for our direct to implant reconstructions and have not seen any specific increase in complication rates (61) and have even seen benefits in reduced capsular contracture rates, even in irradiated patients (62).

**Conclusions**

The technical aspects of NSM surgery vary from practice to practice in the literature and each surgeon has their own biases. The purpose of this review was by no means to endorse any one specific technique but to give an overview of the complexities of the surgery which exist and to offer certain principles and methods to help lower complications rates to get the best results from a standpoint of patient satisfaction and cancer outcome. The best take away information that can be gleamed from my personal experience and this literature review is that nipple viability can best be preserved by not encompassing more than 30% of the nipple in any incision and keeping a 2–3 mm radius of tissue around the nipple bundle when performing the dissection underneath the nipple. The incision should be kept away from the nipple, preferably in the lateral or inferior aspects of the breast, to preserve the blood supply to the skin flaps and to offer the best cosmetic satisfaction results. Skin flaps need to be handled with care (blunt fiberoptic lighted retractors) and the anterior flap needs to be dissected in the glandular dermal plane, leaving as much of the subdermal fat intact (again to prevent vascular damage). This plane varies in thickness from patient to patient. The use of sharp dissection or electrocautery or the peak PlasmaBlade™ (Medtronic, Palo Alto, CA, USA) is at the discretion of the individual surgeon. Patient variables such as BMI, breast size, the need for postoperative radiation, and smoking must also be considered with changes in the technique such as staged reductions, the use of expanders, or even the decision to abandon a NSM and perform a SSM with removal of the nipple in select cases. Coordinated planning of the surgery with an experienced cancer and reconstructive team is of utmost importance to obtain the best patient outcomes. Continual monitoring of complication rates as well as cancer specific outcomes will also ensure the best quality of care for your patients.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* Dr. Ashikari is a consultant for LifeCell Corp. The other authors have no conflicts of interest to declare.

**References**


Cite this article as: Ashikari AY, Kelemen PR, Tastan B, Salzberg CA, Ashikari RH. Nipple sparing mastectomy techniques: a literature review and an inframammary technique. Gland Surg 2018;7(3):273-287. doi: 10.21037/gs.2017.09.02